retatrutide drug retatrutide clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity ESC 2024: Retatrutide improves lipid
Description
It is considered a major public health problem and is the fifth worldwide leading cause of death
Perfil de segurana: o que o farmacutico deve observar Os eventos adversos mais comuns foram semelhantes aos observados com outros agonistas incretnicos: Nuseas Diarreia Constipao Vmitos Reduo do apetite A maioria foi de intensidade leve a moderada
It's a vicious cycle
Best GLP1s editorial approach is centered on provider evaluation and consumer education
The drugs work by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which curbs hunger
